Subscribe to RSS
DOI: 10.1055/s-0029-1219191
Stereoselective Total Synthesis of (-)-Ovalicin
Publication History
Publication Date:
11 January 2010 (online)
Abstract
A new synthetic route for epoxyketone 3 is described, which is a key intermediate in Barton’s synthesis of ovalicin (1), a powerful anti-angiogenetic inhibitor, from commercially available d-ribose. The key reactions involved in this synthesis are ring-closing metathesis, Rubottom oxidation and Corey-Chaykovsky epoxidation. The subsequent transformations are carried out according to Barton’s strategy to complete the total synthesis of (-)-ovalicin.
Keywords
ribose - Rubottom oxidation - ring-closing metathesis - Corey-Chaykovsky epoxidation
-
1a
Sigg HP.Weber HP. Helv. Chim. Acta 1968, 51: 1395 -
1b
Bollinger P.Sigg HP.Weber HP. Helv. Chim. Acta 1973, 56: 819 - 2
Griffith EC.Su Z.Niwayama S.Ramsay CA.Chang Y.-H.Liu JO. Proc. Natl. Acad. Sci. U.S.A. 1998, 95: 15183 - 3
Zimmermann WA.Hartmann GR. Eur. J. Biochem. 1981, 118: 143 - 4
Ingber D.Fujita T.Kishimoto S.Sudo K.Kanamaru T.Brem H.Folkman J. Nature (London) 1990, 348: 555 - 5
Borel JF.Lazary S.Staehelin H. Agents Actions 1974, 4: 357 -
6a
Corey EJ.Dittami JP. J. Am. Chem. Soc. 1985, 107: 256 -
6b
Corey EJ.Guzman-Perez A.Noe MC. J. Am. Chem. Soc. 1994, 116: 12109 -
6c
Barton DHR.Bath S.Billington DD.Gero SD.Quiclet-Sire B.Samadi M. Org. Bioorg. Chem. 1995, 12: 1551 -
6d
Barco A.Benetti S.De Risi C.Marchetti P.Pollini GP.Zanirato V. Tetrahedron: Asymmetry 1998, 9: 2857 -
7a
Yamaguchi J.Toyoshima M.Shoji M.Kakeya H.Osada H.Hayashi Y. Angew. Chem. Int. Ed. 2006, 45: 789 -
7b
Takahashi S.Hishinuma N.Koshino H.Nakata T. J. Org. Chem. 2005, 70: 10162 -
7c
Tiefenbacher K.Arion VB.Mulzer J. Angew. Chem. Int. Ed. 2007, 46: 2690 -
7d
Yadav JS.Sreedhar P.Dinesh CB.Srihari P. Synlett 2007, 992 -
7e
Hua H.Zhao H.Battina K.Lou K.Jimenez L.Desper J.Perchellet M.Perchellet H.Chaiang K. Bioorg. Med. Chem. 2008, 16: 5232 - 8
Leonard NJ.Carraway KL. J. Heterocycl. Chem. 1966, 3: 485 - 9
Garegg PJ.Samuelson B. J. Chem. Soc., Perkin Trans. 1 1980, 2866 - 10
Hyldtoft L.Madsen R. J. Am. Chem. Soc. 2000, 122: 8444 -
11a
Armstrong SK. J. Chem. Soc., Perkin Trans. 1 1998, 371 -
11b
Grubbs RH.Chang S. Tetrahedron 1998, 54: 4413 -
11c
Schuster M.Blechert S. Angew. Chem., Int. Ed. Engl. 1997, 36: 2036 -
11d
Furstner A. Angew. Chem. Int. Ed. 2000, 39: 3013 -
12a
Rubottom GM.Vazquez MA.Pellagrina DR. Tetrahedron Lett. 1974, 4319 -
12b
Rubottom GM.Gruber JM.Juve HD.Charleson DA. Org. Synth. 1986, 64: 118 -
12c
Hassner A.Reuss RH.Pinnick HW. J. Org. Chem. 1975, 40: 3427 -
12d
Brook AG.Macrae DM. J. Organomet. Chem. 1974, 77: C19 - 13
Corey EJ.Kang J.Kyler K. Tetrahedron Lett. 1985, 26: 555 - 14
Pine SH.Shen GS.Hoang H. Synthesis 1991, 165 - 15
Yan T.-H.Tsai C.-C.Chien C.-T.Cho C.-C.Huang P.-C. Org. Lett. 2004, 6: 4961 -
16a
Corey EJ.Chakovsky M. J. Am. Chem. Soc. 1965, 87: 1353 -
16b
Harwood LM.Casy G.Sherlock J. Synth. Commun. 1990, 1287 -
17a
Rodeschini V.Boiteau JG.Weghe PV.Tarnus C.Eustache J. J. Org. Chem. 2004, 69: 357 -
17b
Boiteau JG.Weghe PV.Eustache J. Org. Lett. 2001, 3: 2737 -
17c
Mazitschek R.Huwe A.Giannis A. Org. Biomol. Chem. 2005, 3: 2150 -
17d
Tabber DF.Christos TE.Rheingold AL.Guzei A. J. Am. Chem. Soc. 1999, 121: 5589 -
18a
Kishi Y.Fukuyama T.Natatsuka S. J. Am. Chem. Soc. 1973, 95: 6490 -
18b
Fukuyama T.Natatsuka S.Kishi Y. Tetrahedron 1981, 37: 2045 -
18c
Wu Z.Williams LJ.Danishefsky SJ. Angew. Chem. 2000, 39: 3866 -
18d
Smith AB.Dorsey BD.Visnick M.Maeda T.Malamas MS. J. Am. Chem. Soc. 1986, 108: 3110
References and Notes
Spectroscopic
Data for Selected Products:
(3a
S
,7a
R
)-2,2-Dimethyl-3a,4,5,7a-tetrahydro-1,3-benzodioxol-4-ol
(8): major isomer, brown solid; mp 88-
90 ˚C; [α]D -18.1
(c = 1, CHCl3). IR
(neat): 3440, 2923, 1648, 1373, 1075 cm-¹. ¹H
NMR (300 MHz, CDCl3): δ = 1.37 (s,
3 H), 1.40 (s, 3 H), 1.96 (d, J = 8.7
Hz, 1 H), 2.25 (m, 2 H), 3.83 (m, 1 H), 4.34 (m, 1 H), 4.56 (s,
1 H), 5.69 (m, 2 H). ¹³C NMR (75 MHz,
CDCl3): δ = 126.6, 126.0, 109.4, 76.1,
73.4, 67.1, 28.7, 27.3, 26.3. MS (ESI): m/z = 193 [M + Na]+.
(3a
S
,7a
R
)-2,2-Dimethylperhydro-1,3-benzodioxol-4-ol (9):
mixture of isomers, yellow oil; [α]D -26.6
(c = 1, CHCl3). IR
(neat): 3446, 2937, 1376, 1032, 876 cm-¹. ¹H NMR
(300 MHz, CDCl3): δ = 1.35 (s, 3 H),
1.50 (s, 3 H), 1.54-1.80 (m, 6 H), 2.07 (s, 1 H), 3.68-3.76
(m, 1 H), 4.14-4.22 (m, 2 H). ¹³C
NMR (75 MHz, CDCl3): δ = 108.5, 81.5, 75.7,
74.4, 72.6, 68.2, 30.4, 28.3, 27.6, 27.5, 27.0, 26.7, 26.2, 25.6,
18.6, 17.4. MS (ESI): m/z = 195 [M + Na]+.
(3a
R,7a
R
)-2,2-Dimethylperhydro-1,3-benzodioxol-4-one (10): white solid; mp 112-114 ˚C; [α]D -63.2
(c = 1, CHCl3). IR
(neat): 3447, 2937, 1726, 1376, 1220 cm-¹. ¹H
NMR (200 MHz, CDCl3): δ = 1.36 (s,
3 H), 1.41 (s, 3 H), 1.82-2.06 (m, 3 H), 2.14-2.38
(m, 2 H), 2.43-2.56 (m, 1 H), 4.22 (d, J = 5.4
Hz, 1 H), 4.53-4.61 (m, 1 H). ¹³C
NMR (75 MHz, CDCl3): δ = 208.4, 109.4,
79.1, 39.9, 26.9, 26.7, 25.8, 20.2, 17.4. MS (ESI): m/z = 171 [M + H]+.
(3a
R
,5
R
,7a
R
)-5-[1-(
tert
-Butyl)-1,1-diphenylsilyl]oxy-2,2-dimethylperhydro-1,3-benzodioxol-4-one
(13): colorless liquid; [α]D -62.4
(c = 1.7, CHCl3). ¹H
NMR (300 MHz, CDCl3): δ = 1.08 (s,
9 H), 1.36 (s, 3 H), 1.37 (s, 3 H), 1.73-1.92 (m, 2 H),
1.95-2.05 (m, 1 H), 2.41-2.55 (m, 1 H), 4.18 (dd, J = 2.2, 3.7 Hz, 1 H), 4.61
(m, 1 H), 4.82 (d, J = 5.2 Hz, 1
H), 7.31-7.46 (m, 6 H), 7.50-7.54 (m, 2 H), 7.58-7.62
(m, 2 H). ¹³C NMR (75 MHz, CDCl3): δ = 206.4,
135.5, 135.4, 134.7, 132.9, 130.1, 129.5, 127.8, 127.6, 109.6, 78.5,
77.8, 76.3, 29.2, 26.9, 26.8, 26.5, 26.1, 20.6. MS (ESI): m/z = 447 [M + Na]+.
(7
R
,8
R
,11
R
)-11-[1-(
tert
-Butyl)-1,1-diphenylsilyl]oxy-1,5-dithiaspiro[5.5]undecane-7,8-diol
(14): semi solid; [α]D +16.7
(c = 1.3, CHCl3).
IR (neat): 3446, 2925, 2854, 1109, 702 cm-¹. ¹H
NMR (200 MHz, CDCl3): δ = 1.09 (s,
9 H), 1.32-2.16 (m, 7 H), 2.56-2.70 (m, 1 H),
2.75-2.89 (m, 2 H), 2.92-3.11 (m, 2 H), 3.91 (dd, J = 3.8 Hz, 1 H), 4.08-4.22
(m, 2 H), 7.28-7.47 (m, 6 H), 7.65-7.81 (m, 4
H). ¹³C NMR (75 MHz, CDCl3): δ = 136.5,
135.5, 132.7, 132.2, 130.1, 129.6, 127.8, 127.4, 75.0, 74.4, 73.1,
29.6, 29.2, 27.2, 26.8, 23.3, 19.2. MS (ESI): m/z = 497 [M + Na]+.
(7
R
,8
R
,11
R
)-7-(Acetyloxy)-11-[1-(
tert
-butyl)-1,1-diphenylsilyl]oxy-1,5-dithiaspiro[5.5]undec-8-yl
Acetate (15): semi solid; [α]D +25.2
(c = 1, MeOH). IR (neat): 3451, 2929,
2856, 1743, 1245, 703 cm-¹. ¹H
NMR (300 MHz, CDCl3): δ = 1.10 (s,
9 H), 1.24-1.61 (m, 5 H), 1.93 (s, 3 H), 1.96 (s, 3 H),
2.02-2.16 (m, 1 H), 2.50-2.60 (m, 1 H), 2.74-2.84
(m, 1 H), 2.98-3.10 (m, 1 H), 3.14-3.26 (m, 1
H), 3.88 (dd, J = 4.5, 12.0
Hz, 1 H), 5.53-5.62 (m, 1 H), 5.77 (d, J = 1.5
Hz, 1 H), 7.31-7.41 (m, 6 H), 7.68-7.73 (m, 2
H), 7.76-7.81 (m, 2 H). ¹³C
NMR (75 MHz, CDCl3): δ = 136.3, 136.0, 135.2,
134.7, 129.6, 129.4, 127.5, 127.3, 73.4, 69.1, 60.5, 26.9, 26.5,
25.6, 24.8, 23.5, 20.8, 20.6, 19.6, 18.9. MS (ESI): m/z = 581 [M + Na]+.
(7
R
,8
R
)-7-(Acetyloxy)-11-oxo-1,5-dithiaspiro[5.5]undec-8-yl
Acetate (17): white solid; mp 82-84 ˚C; [α]D +163.1
(c = 1, CHCl3). IR
(neat): 2924, 2854, 1747, 1236, 721 cm-¹. ¹H
NMR (200 MHz, CDCl3): δ = 1.95-2.07
(m, 6 H), 2.11 (s, 3 H), 2.13-2.31 (m, 1 H), 2.41-2.55
(m, 1 H), 2.66-2.84 (m, 2 H), 2.91-3.24 (m, 3
H), 5.72-5.83 (m, 2 H). ¹³C
NMR (75 MHz, CDCl3): δ = 200.9, 170.0,
169.5, 73.9, 67.5, 59.6, 33.8, 26.9, 26.4, 24.6, 24.0, 20.7, 20.4.
MS (ESI): m/z = 319 [M + H]+.
(10
R,11
R
)-10,11-Dihydroxy-1,5-dithiaspiro[5.5]undecan-7-one
(18): white solid; mp 101-103 ˚C; [α]D +145.9
(c = 1, CHCl3). IR
(neat): 3446, 2924, 1705, 1219, 771 cm-¹.
¹H
NMR (300 MHz, CDCl3): δ = 1.25 (s,
1 H), 1.52-1.69 (m, 1 H), 1.76-1.93 (m, 1 H),
2.03-2.26 (m, 2 H), 2.34-2.44 (m, 1 H), 2.60-2.70
(m, 3 H), 2.87-3.03 (m, 1 H), 3.18-3.32 (m, 1
H), 3.52 (d, J = 9.0 Hz, 1 H),
3.70-3.81 (m, 1 H), 4.08-4.18 (m, 1 H). ¹³C
NMR (75 MHz, CDCl3): δ = 202.7, 78.9,
68.4, 67.0, 33.3, 27.3, 26.9, 26.1, 24.2. MS (ESI): m/z = 257 [M + Na]+.
(10
R,11
R
)-10-[1-(
tert
-Butyl)-1,1-dimethylsilyl]oxy-11-hydroxy-1,5-dithiaspiro[5.5]undecan-7-one
(19): semi solid; [α]D +93
(c = 1.25, CHCl3).
IR (neat): 3504, 2928, 2855, 1709, 1109, 837 cm-¹. ¹H
NMR (300 MHz, CDCl3):
δ = 0.12
(s, 3 H), 0.15 (s, 3 H), 0.92 (s, 9 H), 1.42 (s, 1 H), 1.74-1.93
(m, 2 H), 2.01-2.21 (m, 2 H), 2.54-2.68 (m, 3
H), 2.87-3.00 (m, 2 H), 3.26-3.38 (m, 1 H), 3.97
(d, J = 2.2 Hz, 1 H), 4.35-4.42
(m, 1 H). ¹³C NMR (75 MHz, CDCl3): δ = 207.2,
78.2, 77.7, 75.6, 30.8, 29.4, 27.0, 26.1, 25.5, 20.4, 17.9, -5.12, -5.17.
MS (ESI): m/z = 371 [M + Na]+.
tert
-Butyl[(3
S
,10
R
,11
R
)-10-methoxy-1-oxa-5,9-dithiadispiro[2.0.5.4]tridec-11-yl]oxydimethylsilane (21): yellow oil; [α]D -21.9
(c = 0.35, CHCl3).
IR (neat): 3373, 2922, 2853, 2365, 1466, 756 cm-¹. ¹H
NMR (200 MHz, CDCl3): δ = 0.09 (s,
3 H), 0.10 (s, 3 H), 0.90 (s, 9 H), 1.53-2.19 (m, 5 H),
2.37-2.74 (m, 4 H), 3.21-3.40 (m, 2 H), 3.42-3.54
(m, 2 H), 3.56 (s, 3 H), 4.17-4.29 (m, 1 H). ¹³C NMR
(75 MHz, CDCl3): δ = 88.6, 83.0, 71.3,
69.8, 52.7, 32.0, 31.1, 30.6, 29.6, 29.3, 28.1, 27.4, 25.8, 24.5, -4.7.
MS
(ESI): m/z = 399 [M + Na]+.
(3
S
,5
R
,6
R
)-6-[1-(
tert
-Butyl)-1,1-dimethylsilyl]oxy-5-methoxy-1-oxaspiro [2.5]octan-4-one
(3): yellow oil; [α]D -1.20
(c = 1, CH2Cl2).
IR (neat): 2922, 2852, 1737, 1461, 762 cm-¹. ¹H
NMR (200 MHz, CDCl3) : δ = 0.07 (s,
3 H), 0.08 (s, 3 H), 0.92 (s, 9 H), 1.40-1.60 (m, 1 H),
2.00-2.20 (m, 2 H), 2.40-2.60 (m, 1 H), 2.77 (d, J = 4.7 Hz, 1 H), 3.29 (d, J = 4.7 Hz, 1 H), 3.44 (s, 3
H), 3.98 (d, J = 2.5 Hz, 1 H), 4.44
(m, 1 H). ¹³C NMR (75 MHz, CDCl3): δ = 202.4,
87.5, 72.3, 60.7, 58.5, 51.4, 28.9, 27.1, 25.9, 18.3, -4.4, -5.0.
MS (ESI): m/z = 309 [M + Na]+.
(-)-Ovalicin (1): white
solid; mp 94-95 ˚C; [α]D -112
(c = 0.2, CHCl3).
IR (neat): 3438, 2923, 2853, 1728, 1627, 1459, 1216, 761 cm-¹. ¹H
NMR (500 MHz, CDCl3): δ = 1.37 (s,
3 H), 1.41-1.45 (m, 1 H), 1.66 (s, 3 H), 1.75 (s, 3 H),
2.12-2.18 (m, 1 H), 2.30-2.45 (m, 2 H), 2.61-2.71
(m, 2 H), 2.73 (d,
J = 4.2
Hz, 1 H), 2.90 (t, J = 6.3 Hz,
1 H), 3.10 (d, J = 4.2 Hz, 1
H), 3.14 (s, 1 H), 3.57 (s, 3 H), 4.23 (s, 1 H), 5.18 (t,
J = 6.6 Hz, 1 H). ¹³C
NMR (75 MHz, CDCl3): δ = 206.8, 135.7,
118.2, 86.3, 78.8, 60.7, 60.5, 59.5, 57.0, 51.5, 36.9, 30.5, 27.2,
25.9, 18.2, 14.6. MS (ESI): m/z = 319 [M + Na]+.